NEW YORK, October 13, 2014 /PRNewswire/ --
Today, Analysts Review released its research reports regarding Exxon Mobil Corporation (NYSE: XOM), Halliburton Company (NYSE: HAL), Chevron Corporation (NYSE: CVX), Schlumberger Limited (NYSE: SLB) and Monsanto Company (NYSE: MON). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7121-100free.
--
Exxon Mobil Corporation Research Reports
On October 2, 2014, Exxon Mobil Corporation (ExxonMobil) announced that it has donated grants worth $18 million to Houston healthcare facilities. According to the Company, grants worth $10 million will be provided to The University of Texas MD Anderson Cancer Center to support strategies aimed at reducing the danger of developing cancer and other chronic disease in a community to be selected in the Houston area. Texas Heart Institute will receive $5 million from the grant to support its research on cardiovascular diseases, while the remaining $3 million will be given to Texas Children's Hospital to aid clinical research for children, including the cure for life-threatening liver diseases. The Hospital will use the funds to expand services for children with autism and other behavioral and developmental disabilities. The full research reports on ExxonMobil are available to download free of charge at:
http://www.analystsreview.com/Oct-13-2014/XOM/report.pdf
--
Halliburton Company Research Reports
On October 8, 2014, Halliburton Company (Halliburton) announced it has been awarded with a long term contract from Petroamazonas - Ecuador's state-run oil company, to provide field development and project management, as well as drilling and completions services, across nine mature fields, including the Palo Azul, Lago Agrio and Victor Hugo Ruales fields. The contract period is of 15 years with a potential five-year extension. Halliburton said that it plans to invest c.$1 billion during the first five years to improve oil recovery from existing wells and encounter new hydrocarbon reserves. Jim Brown, President of Halliburton's Western Hemisphere, said, "The development and deployment of Halliburton's technology to improve production from previously produced reservoirs will immediately assist Petroamazonas' objective to maximize the value of these mature assets." The full research reports on Halliburton are available to download free of charge at:
http://www.analystsreview.com/Oct-13-2014/HAL/report.pdf
--
Chevron Corporation Research Reports
On October 6, 2014, Chevron Corporation (Chevron) announced that its indirect, wholly-owned subsidiary, Chevron Canada Limited, has agreed to sell its 30% stake in its Duvernay shale play to Kuwait Foreign Petroleum Exploration Company's wholly-owned subsidiary, KUFPEC Canada Inc., for $1.5 billion. Following the transaction, Chevron Canada Limited will own a 70% interest in the joint venture Duvernay acreage and will continue as the operator. The transaction is likely to get completed in November 2014. Jay Johnson, Senior Vice President, Upstream, Chevron, said, "This sale demonstrates our focus on strategically managing our portfolio to maximize the value of our global upstream businesses and is consistent with our partnership strategy." The full research reports on Chevron are available to download free of charge at:
http://www.analystsreview.com/Oct-13-2014/CVX/report.pdf
--
Schlumberger Limited Research Reports
As per the Events Calendar of Schlumberger Limited (Schlumberger), the Company is scheduled to host a conference call on October 17, 2014, at 8:00 a.m. ET to review its Q3 2014 financial results. As per analysts polled by Bloomberg Businessweek, the Company is expected to report an EPS (Pre-Exceptional) of $1.49 on revenue of $12.7 billion in Q3 2014. The full research reports on Schlumberger are available to download free of charge at:
http://www.analystsreview.com/Oct-13-2014/SLB/report.pdf
--
Monsanto Company Research Reports
On October 8, 2014, Monsanto Company (Monsanto) announced its FY 2014 financial results (period ended August 31, 2014), slightly above the upper bound of the Company's own guidance range. Net sales for the year came in at $15.9 billion, up 6.7% YoY, driven by the strength of the Seeds and Genomics segment, including a record year for the Company's soybean business. Monsanto reported an EPS of $5.23 on an ongoing basis. For Q4 FY 2014, the Company reported a loss of 31 cents per share. Losses, adjusted for non-recurring costs, came to 27 cents per share, lagging the average estimate of 24 cents per share by analysts surveyed by Zacks Investment Research. For FY 2015, the Company expects an EPS of $5.75 to $6.00, which is expected to be driven by the Seeds and Genomics segment. The Company said that it expects double-digit gross profit growth in its Seeds and Genomics segment in FY 2015, with more than three-quarters of the growth opportunity expected to come from its core corn and soybean businesses. The full research reports on Monsanto are available to download free of charge at:
http://www.analystsreview.com/Oct-13-2014/MON/report.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
